Advice

in the absence of a submission from the holder of the marketing authorisation:

trastuzumab deruxtecan (Enhertu®) is not recommended for use within NHSScotland.

Indication under review: for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours who have received prior treatment or who have no satisfactory alternative treatment options.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result, we cannot recommend its use within NHSScotland.

The holder of the marketing authorisation has indicated that they plan to make a submission to SMC in the future.

Download detailed advice195KB (PDF)

Download

Medicine details

Medicine name:
trastuzumab deruxtecan (Enhertu)
SMC ID:
SMC2854
Indication:

For the treatment of adult patients with unresectable or metastatic HER2-positive (IHC3+) solid tumours who have received prior treatment or who have no satisfactory alternative treatment options.

Pharmaceutical company
Daiichi Sankyo UK Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Status
Not recommended
Date advice published
11 August 2025